【摘要】 目的研究鼻咽癌后程加速超分割放疗对鼻咽局部控制、生存的影响和并发症状况。方法全组178例鼻咽癌患者于1995年12月至1998年4月行首次单纯放疗,鼻咽原发灶采用⁶⁰Coγ线或6 MV X线外照射,其中前4周采用超分割1．2Gy/次,2次/d,5d/周,间隔≥6h,剂量为48Gy分40次；后2周采用加速超分割1．5Gy/次,2次/d,间隔≥6h,5d/周,剂量为30Gy分20次,全疗程的总剂量为78Gy分60次6周完成。结果急性黏膜反应中鼻咽黏膜反应0级仪2例,1级43例,2级78例,3级52例,4级3例。鼻咽5年局部控制率为87．7%,颈部5年局部控制率为85．7%。5年生存率为67．9%。5年远处转移率为26．1%,颅神经损伤占9．0%。结论该方法患者能耐受,5年局部控制率、生存率比常规分割和超分割有所提高,颅神经等晚期放射性损伤未见明显增加。更多还原

【Abstract】 Objective To study the efficacy of late course accelerated fractionation（LCAF） radio- therapy in the treatment of nasopharyngeal carcinoma（NPC）.The end-po s were local control,radiation-in- duced complications,factors influencing survival.Methods From December 1995 to April 1998,178 NPC patients were admitted for radiation treatment.The radiation beam used was ⁶⁰Coγor 6 MV X-ray.For the first two-thirds of the treatment,two daily fractions of 1.2 Gy were given to the primary lesion ,with an interval of≥6 hours,5 days per week to a total dose of 48 Gy/40 fractions,over a period of 4 weeks.For the last one third of the treatment,i.e.beginning from the 5th week,an accelerated hyperfractionation schedule was carried out.The dose per fraction was increased to 1.5 Gy,2 fractions per day with an interval of≥6 hours,the total dose for this part of the protocol was 30 Gy/20 fractions over 2 weeks.Thus the total dose was 78 Gy in 60 fractions in 6 weeks.Results All patients completed the treatment.Acute mucosi- tis:none in 2 patients,Grade 1 in 43,Grade 2 in 78,Grade 3 in 52,and Grade 4 in 3 patients.Local control rate:the 5-year nasopharyngeal local control rate was 87.7%,and the cervical lymph node local control rate was 85.7%.The 5-year distant metastasis rate was 26.1%,and 5-year survivals was 67.9%. Sixteen patients had radiation-induced cranial nerve palsy.Conclusions With this treatment schedule, patient’s tolerance is good,local control and 5 year survivals are better than control groups of conventional fractionation and hyperfractionation radiotherapy.Radiation-related late complication does not increase.Ran- domized clinical trials are being carried out to further confirm the efficacy of LCAF for nasopharyngeal carci- noma.更多还原